SNSS - Sunesis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue2,5363,0615,734
Cost of Revenue---
Gross Profit2,5363,0615,734
Operating Expenses
Research Development22,88123,70127,665
Selling General and Administrative16,11518,66223,112
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-36,460-39,302-45,043
Income from Continuing Operations
Total Other Income/Expenses Net1583,5653,760
Earnings Before Interest and Taxes-36,302-35,737-41,283
Interest Expense1,7219391,719
Income Before Tax-38,023-36,676-43,002
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-38,023-36,676-43,002
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-38,023-36,676-43,002
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-38,023-36,676-43,002